文献速递肾小球疾病

奥妥珠单抗与奥法木单抗在抗利妥昔单抗抗体阳性膜性肾病患者中优于利妥昔单抗

Obinutuzumab and Ofatumumab are More Effective Than Rituximab in the Treatment of Membranous Nephropathy Patients With Anti-Rituximab Antibodies.
PubMed 文献 · Kidney Int Rep · 2024-12-17

结果显示奥妥珠单抗或奥法木单抗组第6个月和第12个月临床缓解率均显著高于利妥昔单抗组。

要点

  • 抗利妥昔单抗抗体阳性膜性肾病患者换用奥妥珠单抗或奥法木单抗可能提高缓解率
  • 奥妥珠单抗或奥法木单抗组第6个月临床缓解率87% vs 利妥昔单抗组37%
  • 应系统监测抗利妥昔单抗抗体以指导治疗选择

核心结论

  • 在伴有抗利妥昔单抗抗体的膜性肾病患者中,奥妥珠单抗和奥法木单抗比利妥昔单抗更有效。
  • 抗利妥昔单抗抗体应被系统监测,以确定合适的治疗。

研究设计与样本

  • 国际回顾性多中心研究,纳入法国、印度和意大利5个肾内科的34例膜性肾病患者。

主要发现

  • 奥妥珠单抗或奥法木单抗组第6个月临床缓解率高于利妥昔单抗组(87% vs 37%,P = 0.005)。
  • 奥妥珠单抗或奥法木单抗组第12个月临床缓解率高于利妥昔单抗组(87% vs 42%,P = 0.01)。
  • 奥妥珠单抗或奥法木单抗组第6个月免疫学缓解率高于利妥昔单抗组(92% vs 56%,P = 0.04)。
  • 奥妥珠单抗或奥法木单抗组第6个月B细胞耗竭率高于利妥昔单抗组(93% vs 35%,P = 0.002)。
  • 奥妥珠单抗或奥法木单抗组未报告严重不良事件。

关键数值与推荐

  • 临床缓解:第6个月87% vs 37%(P = 0.005),第12个月87% vs 42%(P = 0.01),比较奥妥珠单抗或奥法木单抗组与利妥昔单抗组。
  • 免疫学缓解:第6个月92% vs 56%(P = 0.04),比较奥妥珠单抗或奥法木单抗组与利妥昔单抗组。
  • B细胞耗竭:第6个月93% vs 35%(P = 0.002),比较奥妥珠单抗或奥法木单抗组与利妥昔单抗组。

临床怎么用

  • 对膜性肾病患者应系统监测抗利妥昔单抗抗体。
  • 抗利妥昔单抗抗体阳性患者可考虑换用奥妥珠单抗或奥法木单抗。

局限性

  • 回顾性研究设计。
  • 样本量小(共34例,奥法木单抗组仅3例)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Although rituximab has significantly improved outcomes for patients with membranous nephropathy, response to treatment is not universal and drug resistance can occur. One mechanism of resistance is the occurrence of antidrug antibodies. Obinutuzumab and ofatumumab are humanized and human monoclonal antibodies, respectively, that target B cells. These treatments have been shown to be effective in membranous nephropathy. However, obinutuzumab and ofatumumab have never been compared with rituximab in the treatment of patients with membranous nephropathy with anti-rituximab antibodies. We aimed to compare the efficacy and safety of obinutuzumab and ofatumumab with rituximab in patients with membranous nephropathy with anti-rituximab antibodies. METHODS: This international retrospective multicenter study enrolled 34 patients with membranous nephropathy from 5 nephrology departments in France, India, and Italy. All the patients had previously developed anti-rituximab antibodies. Nineteen patients received rituximab, 12 received obinutuzumab, and 3 received ofatumumab. RESULTS: Patients treated with obinutuzumab or ofatumumab were more likely to achieve clinical remission than those treated with rituximab at month 6 (87% vs. 37%, P = 0.005) and month 12 (87% vs. 42%, P = 0.01). Patients treated with obinutuzumab or ofatumumab were more likely to achieve immunological remission and B-cell depletion at month 6 than the patients treated with rituximab (92% vs. 56%, P = 0.04 and 93% vs. 35%, P = 0.002, respectively). No serious adverse events were reported in the obinutuzumab or ofatumumab group. CONCLUSION: Obinutuzumab and ofatumumab are more effective than rituximab in treating patients with membranous nephropathy with anti-rituximab antibodies. Anti-rituximab antibodies should be systematically monitored, to determine appropriate treatment.

来源:Kidney Int Rep,查看原文。版权归原作者所有。

引用

  1. Teisseyre M, Allinovi M, Audard V, et al. Obinutuzumab and Ofatumumab are More Effective Than Rituximab in the Treatment of Membranous Nephropathy Patients With Anti-Rituximab Antibodies. Kidney Int Rep. 2024. PMID: 40225374. doi:10.1016/j.ekir.2024.12.012

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。